UnitedHealth Group, Eli Lilly and Company, Merck & Co., Inc., AbbVie, and Gilead Sciences are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Medical stocks within the last several days.
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Shares of UNH stock traded down $6.05 during trading on Friday, hitting $418.20. 9,255,934 shares of the stock traded hands, compared to its average volume of 4,475,126. The firm has a market capitalization of $382.53 billion, a P/E ratio of 26.98, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.83 and a quick ratio of 0.91. UnitedHealth Group has a 52-week low of $412.02 and a 52-week high of $630.73. The firm's fifty day moving average price is $503.28 and its 200-day moving average price is $535.01.
Read Our Latest Research Report on UNH
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
LLY stock traded up $25.21 during mid-day trading on Friday, hitting $884.94. 3,395,903 shares of the company were exchanged, compared to its average volume of 3,439,006. The business has a fifty day simple moving average of $827.69 and a 200-day simple moving average of $818.61. The firm has a market capitalization of $839.07 billion, a P/E ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.
Read Our Latest Research Report on LLY
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
NYSE MRK traded up $2.99 on Friday, reaching $82.83. The stock had a trading volume of 28,374,477 shares, compared to its average volume of 11,891,688. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The stock has a fifty day moving average price of $87.05 and a two-hundred day moving average price of $95.23. Merck & Co., Inc. has a 12-month low of $75.93 and a 12-month high of $134.63. The firm has a market capitalization of $208.88 billion, a price-to-earnings ratio of 12.31, a P/E/G ratio of 0.77 and a beta of 0.40.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV traded up $5.59 during mid-day trading on Friday, hitting $185.96. 10,480,961 shares of the stock were exchanged, compared to its average volume of 6,064,215. The firm's fifty day moving average is $196.85 and its two-hundred day moving average is $187.23. AbbVie has a 1-year low of $153.58 and a 1-year high of $218.66. The company has a market cap of $328.96 billion, a PE ratio of 77.48, a PEG ratio of 1.62 and a beta of 0.55. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94.
Read Our Latest Research Report on ABBV
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of NASDAQ GILD traded down $2.98 during midday trading on Friday, hitting $103.17. The company's stock had a trading volume of 14,207,970 shares, compared to its average volume of 7,526,289. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $119.96. The business's fifty day simple moving average is $109.21 and its two-hundred day simple moving average is $98.15. The firm has a market capitalization of $128.46 billion, a price-to-earnings ratio of 278.84, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Read Our Latest Research Report on GILD
Featured Articles
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
